<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p23" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_23{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_23{left:341px;bottom:30px;}
#t3_23{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_23{left:377px;bottom:30px;}
#t5_23{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_23{left:540px;bottom:30px;}
#t7_23{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_23{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_23{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_23{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_23{left:285px;bottom:827px;letter-spacing:-0.26px;}
#tc_23{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_23{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_23{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_23{left:1106px;bottom:47px;letter-spacing:0.34px;}
#tg_23{left:1121px;bottom:28px;letter-spacing:0.19px;word-spacing:-0.15px;}
#th_23{left:36px;bottom:298px;}
#ti_23{left:46px;bottom:292px;letter-spacing:-0.07px;word-spacing:-0.01px;}
#tj_23{left:370px;bottom:292px;letter-spacing:-0.04px;}
#tk_23{left:399px;bottom:292px;letter-spacing:-0.02px;}
#tl_23{left:471px;bottom:292px;}
#tm_23{left:36px;bottom:282px;}
#tn_23{left:46px;bottom:276px;letter-spacing:-0.03px;word-spacing:-0.08px;}
#to_23{left:36px;bottom:267px;}
#tp_23{left:46px;bottom:261px;letter-spacing:-0.06px;word-spacing:0.02px;}
#tq_23{left:45px;bottom:246px;letter-spacing:-0.04px;}
#tr_23{left:45px;bottom:231px;letter-spacing:-0.06px;word-spacing:-0.07px;}
#ts_23{left:45px;bottom:215px;letter-spacing:-0.03px;}
#tt_23{left:36px;bottom:206px;}
#tu_23{left:46px;bottom:200px;letter-spacing:-0.05px;word-spacing:0.02px;}
#tv_23{left:45px;bottom:185px;letter-spacing:-0.04px;word-spacing:0.01px;}
#tw_23{left:45px;bottom:170px;letter-spacing:-0.04px;}
#tx_23{left:36px;bottom:160px;}
#ty_23{left:46px;bottom:154px;letter-spacing:0.09px;word-spacing:0.03px;}
#tz_23{left:45px;bottom:139px;letter-spacing:0.13px;}
#t10_23{left:36px;bottom:130px;}
#t11_23{left:46px;bottom:124px;letter-spacing:0.13px;word-spacing:-0.05px;}
#t12_23{left:45px;bottom:108px;letter-spacing:0.03px;}
#t13_23{left:110px;bottom:108px;}
#t14_23{left:438px;bottom:778px;letter-spacing:0.39px;word-spacing:-0.22px;}
#t15_23{left:765px;bottom:786px;}
#t16_23{left:36px;bottom:764px;letter-spacing:-0.1px;}
#t17_23{left:36px;bottom:749px;letter-spacing:-0.11px;word-spacing:-0.62px;}
#t18_23{left:36px;bottom:734px;letter-spacing:-0.1px;}
#t19_23{left:41px;bottom:719px;}
#t1a_23{left:58px;bottom:719px;letter-spacing:-0.09px;}
#t1b_23{left:58px;bottom:703px;letter-spacing:-0.09px;}
#t1c_23{left:63px;bottom:688px;}
#t1d_23{left:76px;bottom:688px;letter-spacing:-0.09px;}
#t1e_23{left:77px;bottom:673px;}
#t1f_23{left:91px;bottom:673px;letter-spacing:-0.09px;}
#t1g_23{left:91px;bottom:657px;letter-spacing:-0.09px;}
#t1h_23{left:91px;bottom:642px;letter-spacing:-0.1px;}
#t1i_23{left:77px;bottom:627px;letter-spacing:-0.09px;word-spacing:-0.03px;}
#t1j_23{left:479px;bottom:634px;}
#t1k_23{left:91px;bottom:612px;letter-spacing:-0.1px;}
#t1l_23{left:365px;bottom:619px;}
#t1m_23{left:77px;bottom:596px;letter-spacing:-0.16px;word-spacing:0.01px;}
#t1n_23{left:92px;bottom:581px;letter-spacing:-0.09px;}
#t1o_23{left:103px;bottom:566px;letter-spacing:-0.09px;}
#t1p_23{left:92px;bottom:550px;}
#t1q_23{left:103px;bottom:550px;letter-spacing:-0.09px;}
#t1r_23{left:77px;bottom:535px;letter-spacing:-0.09px;word-spacing:-0.03px;}
#t1s_23{left:91px;bottom:520px;letter-spacing:-0.08px;}
#t1t_23{left:77px;bottom:505px;letter-spacing:-0.09px;word-spacing:-0.03px;}
#t1u_23{left:41px;bottom:489px;}
#t1v_23{left:58px;bottom:489px;letter-spacing:-0.09px;}
#t1w_23{left:63px;bottom:474px;}
#t1x_23{left:76px;bottom:474px;letter-spacing:-0.09px;}
#t1y_23{left:77px;bottom:459px;letter-spacing:-0.1px;}
#t1z_23{left:539px;bottom:466px;}
#t20_23{left:36px;bottom:444px;}
#t21_23{left:47px;bottom:444px;letter-spacing:-0.1px;word-spacing:0.01px;}
#t22_23{left:47px;bottom:428px;letter-spacing:-0.09px;}
#t23_23{left:47px;bottom:413px;letter-spacing:-0.2px;}
#t24_23{left:152px;bottom:420px;}
#t25_23{left:774px;bottom:509px;letter-spacing:-0.09px;}
#t26_23{left:774px;bottom:491px;letter-spacing:-0.1px;}
#t27_23{left:774px;bottom:473px;letter-spacing:-0.09px;}
#t28_23{left:774px;bottom:454px;letter-spacing:-0.09px;}
#t29_23{left:774px;bottom:436px;letter-spacing:-0.09px;}
#t2a_23{left:774px;bottom:418px;letter-spacing:-0.1px;}
#t2b_23{left:774px;bottom:399px;letter-spacing:-0.13px;word-spacing:0.03px;}
#t2c_23{left:774px;bottom:381px;letter-spacing:-0.1px;}
#t2d_23{left:774px;bottom:363px;letter-spacing:-0.1px;}
#t2e_23{left:775px;bottom:748px;letter-spacing:0.34px;word-spacing:-0.18px;}
#t2f_23{left:1116px;bottom:755px;letter-spacing:-0.12px;}
#t2g_23{left:774px;bottom:729px;letter-spacing:-0.08px;}
#t2h_23{left:780px;bottom:711px;}
#t2i_23{left:797px;bottom:711px;letter-spacing:-0.12px;word-spacing:0.03px;}
#t2j_23{left:780px;bottom:693px;}
#t2k_23{left:797px;bottom:693px;letter-spacing:-0.09px;}
#t2l_23{left:796px;bottom:674px;letter-spacing:-0.09px;}
#t2m_23{left:1128px;bottom:682px;}
#t2n_23{left:532px;bottom:313px;}
#t2o_23{left:543px;bottom:307px;letter-spacing:0.12px;word-spacing:0.01px;}
#t2p_23{left:541px;bottom:292px;letter-spacing:0.12px;}
#t2q_23{left:541px;bottom:276px;letter-spacing:0.13px;}
#t2r_23{left:871px;bottom:284px;}
#t2s_23{left:876px;bottom:276px;letter-spacing:0.13px;}
#t2t_23{left:541px;bottom:261px;letter-spacing:0.12px;word-spacing:0.01px;}
#t2u_23{left:541px;bottom:246px;letter-spacing:0.13px;}
#t2v_23{left:541px;bottom:231px;letter-spacing:0.12px;}
#t2w_23{left:541px;bottom:215px;letter-spacing:0.1px;word-spacing:0.03px;}
#t2x_23{left:541px;bottom:200px;letter-spacing:0.12px;word-spacing:-0.04px;}
#t2y_23{left:541px;bottom:185px;letter-spacing:0.12px;}
#t2z_23{left:541px;bottom:170px;letter-spacing:0.11px;word-spacing:0.01px;}
#t30_23{left:541px;bottom:154px;letter-spacing:0.11px;word-spacing:0.01px;}
#t31_23{left:541px;bottom:139px;letter-spacing:0.12px;}
#t32_23{left:541px;bottom:124px;letter-spacing:0.12px;word-spacing:0.01px;}
#t33_23{left:541px;bottom:108px;letter-spacing:0.12px;}
#t34_23{left:833px;bottom:108px;letter-spacing:0.14px;}
#t35_23{left:939px;bottom:108px;}
#t36_23{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_23{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_23{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_23{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_23{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_23{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_23{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_23{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_23{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s8_23{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s9_23{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sa_23{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sb_23{font-size:17px;font-family:Webdings_k6;color:#000;}
.sc_23{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sd_23{font-size:17px;font-family:SymbolMT_ka;color:#000;}
.se_23{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts23" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

@font-face {
	font-family: SymbolMT_ka;
	src: url("fonts/SymbolMT_ka.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg23Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg23" style="-webkit-user-select: none;"><object width="1210" height="935" data="23/23.svg" type="image/svg+xml" id="pdf23" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_23" class="t s0_23">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_23" class="t s1_23">® </span>
<span id="t3_23" class="t s0_23">(NCCN </span>
<span id="t4_23" class="t s1_23">® </span>
<span id="t5_23" class="t s0_23">), All rights reserved. NCCN Guidelines </span>
<span id="t6_23" class="t s1_23">® </span>
<span id="t7_23" class="t s0_23">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_23" class="t s2_23">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_23" class="t s2_23">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_23" class="t s3_23">NCCN Guidelines Version 4.2024 </span>
<span id="tb_23" class="t s3_23">Cancer of the Oropharynx </span>
<span id="tc_23" class="t s4_23">NCCN Guidelines Index </span>
<span id="td_23" class="t s4_23">Table of Contents </span>
<span id="te_23" class="t s4_23">Discussion </span>
<span id="tf_23" class="t s5_23">ORPH-A </span>
<span id="tg_23" class="t s5_23">1 OF 2 </span>
<span id="th_23" class="t s6_23">1 </span>
<span id="ti_23" class="t s7_23">See Principles of Radiation Techniques (RAD-A) </span><span id="tj_23" class="t s8_23">and </span><span id="tk_23" class="t s7_23">Discussion</span><span id="tl_23" class="t s8_23">. </span>
<span id="tm_23" class="t s6_23">2 </span>
<span id="tn_23" class="t s8_23">Eisbruch A, et al. Int J Radiat Oncol Biol Phys 2010;76:1333-1338. </span>
<span id="to_23" class="t s6_23">3 </span>
<span id="tp_23" class="t s8_23">For doses &gt;70 Gy, some clinicians feel that the fractionation should </span>
<span id="tq_23" class="t s8_23">be slightly modified (eg, &lt;2.0 Gy/fraction for at least some of the </span>
<span id="tr_23" class="t s9_23">treatment) to minimize toxicity. An additional 2–3 doses can be </span>
<span id="ts_23" class="t s8_23">added depending on clinical circumstances. </span>
<span id="tt_23" class="t s6_23">4 </span>
<span id="tu_23" class="t s8_23">Suggest 44–50 Gy in 3D-CRT and sequentially planned IMRT or </span>
<span id="tv_23" class="t s8_23">54–63 Gy with IMRT dose painting technique (dependent on dose </span>
<span id="tw_23" class="t s8_23">per fraction). </span>
<span id="tx_23" class="t s6_23">5 </span>
<span id="ty_23" class="t s8_23">Yom SS, et al. J Clin Oncol 2021;39:956-965; Chera BS, et al. J </span>
<span id="tz_23" class="t s8_23">Clin Oncol 2019;37:2661-2669. </span>
<span id="t10_23" class="t s6_23">6 </span>
<span id="t11_23" class="t s7_23">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers </span>
<span id="t12_23" class="t s7_23">(SYST-A)</span><span id="t13_23" class="t s8_23">. </span>
<span id="t14_23" class="t s5_23">PRINCIPLES OF RADIATION THERAPY </span>
<span id="t15_23" class="t sa_23">1 </span>
<span id="t16_23" class="t s5_23">DEFINITIVE: </span>
<span id="t17_23" class="t s5_23">RT Alone </span>
<span id="t18_23" class="t s5_23">• PTV </span>
<span id="t19_23" class="t sb_23"></span><span id="t1a_23" class="t s5_23">High risk: Primary tumor and involved lymph nodes [this includes possible local </span>
<span id="t1b_23" class="t sc_23" data-mappings='[[14,"fi"]]'>subclinical inﬁltration at the primary site and at the high-risk level lymph node(s)] </span>
<span id="t1c_23" class="t sd_23">◊ </span><span id="t1d_23" class="t s5_23">Fractionation: </span>
<span id="t1e_23" class="t s5_23">– </span><span id="t1f_23" class="t sc_23">IMRT planning can consist of sequential IMRT (S-IMRT) or simultaneous integrated </span>
<span id="t1g_23" class="t sc_23">boost (SIB) techniques. Equivalent doses in 2 Gy (EQD2) can be used to determine </span>
<span id="t1h_23" class="t sc_23">appropriate fractionation schemes when using SIB techniques. </span>
<span id="t1i_23" class="t s5_23">– 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); </span>
<span id="t1j_23" class="t sa_23">2 </span>
<span id="t1k_23" class="t s5_23">daily Monday–Friday in 6–7 weeks </span>
<span id="t1l_23" class="t sa_23">3 </span>
<span id="t1m_23" class="t s5_23">– Concomitant boost accelerated RT: </span>
<span id="t1n_23" class="t sc_23" data-mappings='[[40,"fi"]]'>▪ 72 Gy/6 weeks (1.8 Gy/fraction, large ﬁeld; 1.5 Gy boost as second daily fraction </span>
<span id="t1o_23" class="t s5_23">during last 12 treatment days) </span>
<span id="t1p_23" class="t sc_23">▪ </span><span id="t1q_23" class="t s5_23">66–70 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated) </span>
<span id="t1r_23" class="t s5_23">– Hyperfractionation for T2,N0–1 disease: 81.6 Gy/7 weeks (1.2 Gy/fraction, twice </span>
<span id="t1s_23" class="t s5_23">daily) </span>
<span id="t1t_23" class="t s5_23">– 69.96 Gy (2.12 Gy/fraction) daily Monday–Friday in 6–7 weeks </span>
<span id="t1u_23" class="t sb_23"></span><span id="t1v_23" class="t s5_23">Low to intermediate risk: Sites of suspected subclinical spread </span>
<span id="t1w_23" class="t sd_23">◊ </span><span id="t1x_23" class="t sc_23" data-mappings='[[74,"fi"]]'>44–50 Gy (2.0 Gy/fraction) used for S-IMRT or the use of an anterior neck ﬁeld and to </span>
<span id="t1y_23" class="t sc_23">54–63 Gy (1.6–1.8 Gy/fraction) when using SIB techniques </span>
<span id="t1z_23" class="t sa_23">4 </span>
<span id="t20_23" class="t s5_23">• </span><span id="t21_23" class="t sc_23" data-mappings='[[20,"fi"]]'>Treatment de-intensiﬁcation is an area of active research, with several published phase </span>
<span id="t22_23" class="t s5_23">II studies demonstrating promising rates of progression-free survival with dose-reduced </span>
<span id="t23_23" class="t s5_23">radiotherapy. </span>
<span id="t24_23" class="t sa_23">5 </span>
<span id="t25_23" class="t s5_23">Either IMRT (preferred) or 3D-CRT is </span>
<span id="t26_23" class="t s5_23">recommended for cancers of the oropharynx </span>
<span id="t27_23" class="t s5_23">in order to minimize dose to critical structures. </span>
<span id="t28_23" class="t s5_23">Use of proton therapy is an area of active </span>
<span id="t29_23" class="t s5_23">investigation. Proton therapy may be considered </span>
<span id="t2a_23" class="t s5_23">when normal tissue constraints cannot be met </span>
<span id="t2b_23" class="t s5_23">by photon-based therapy, or when photon-based </span>
<span id="t2c_23" class="t s5_23">therapy causes compromise of standard radiation </span>
<span id="t2d_23" class="t s5_23">dosing to tumor or postoperative volumes. </span>
<span id="t2e_23" class="t s5_23">CONCURRENT SYSTEMIC THERAPY/RT: </span>
<span id="t2f_23" class="t sa_23">6,7 </span>
<span id="t2g_23" class="t s5_23">• PTV </span>
<span id="t2h_23" class="t sb_23"></span><span id="t2i_23" class="t s5_23">High risk: Typically 70 Gy (2.0 Gy/fraction) </span>
<span id="t2j_23" class="t sb_23"></span><span id="t2k_23" class="t s5_23">Low to intermediate risk: 44–50 Gy (2.0 Gy/ </span>
<span id="t2l_23" class="t s5_23">fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t2m_23" class="t sa_23">4 </span>
<span id="t2n_23" class="t s6_23">7 </span>
<span id="t2o_23" class="t s8_23">Based on published data, concurrent systemic therapy/RT most commonly uses conventional </span>
<span id="t2p_23" class="t s8_23">fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single- </span>
<span id="t2q_23" class="t s8_23">agent cisplatin given every 3 weeks at 100 mg/m </span>
<span id="t2r_23" class="t s0_23">2 </span>
<span id="t2s_23" class="t s8_23">; 2–3 cycles of chemotherapy are used </span>
<span id="t2t_23" class="t s8_23">depending on the radiation fractionation scheme (RTOG 0129) (Ang KK, et al. N Engl J </span>
<span id="t2u_23" class="t s8_23">Med 2010;363:24-35). When carboplatin and 5-FU are used, the recommended regimen </span>
<span id="t2v_23" class="t s8_23">is standard fractionation plus 3 cycles of chemotherapy (Bourhis J, et al. Lancet Oncol </span>
<span id="t2w_23" class="t s9_23">2012;13:145-153). Other fraction sizes (eg, 1.8 Gy, conventional), multiagent chemotherapy, </span>
<span id="t2x_23" class="t s8_23">other dosing schedules of cisplatin, or altered fractionation with chemotherapy are efficacious, </span>
<span id="t2y_23" class="t s8_23">and there is no consensus on the optimal approach. In general, the use of concurrent </span>
<span id="t2z_23" class="t s8_23">systemic therapy/RT carries a high toxicity burden; multiagent chemotherapy will likely </span>
<span id="t30_23" class="t s8_23">further increase the toxicity burden. For any systemic therapy/RT approach, close attention </span>
<span id="t31_23" class="t s8_23">should be paid to published reports for the specific chemotherapy agent, dose, and schedule </span>
<span id="t32_23" class="t s8_23">of administration. Systemic therapy/RT should be performed by an experienced team and </span>
<span id="t33_23" class="t s8_23">should include substantial supportive care. </span><span id="t34_23" class="t s7_23">See Discussion</span><span id="t35_23" class="t s8_23">. </span>
<span id="t36_23" class="t se_23">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
